Search research articles
Contact Us
Filters
Showing results (221-230 of 246) with videos related to
Page
of 25
Sort By:
Antimicrobial Agents and Chemotherapy
|
February 1, 2017
Some Synonymous and Nonsynonymous <i>gyrA</i> Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDR<i>sl</i> Assays
Adebisi Ajileye, Nataly Alvarez, Matthias Merker, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 24, 2008
P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice
Jere E Meredith, Lorin A Thompson, Jeremy H Toyn, et al.
Journal of Pharmaceutical Sciences
|
October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations
Kan He, Mingxin Qian, Harvey Wong, et al.
PLOS Global Public Health
|
August 23, 2024
Correction: The effect of M. tuberculosis lineage on clinical phenotype
Duc Hong Du, Ronald B Geskus, Yanlin Zhao, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2010
Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1
Lawrence R Marcin, Mendi A Higgins, F Christopher Zusi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 30, 2023
The effect of <i>M. tuberculosis</i> lineage on clinical phenotype
Duc Hong Du, Ronald B Geskus, Yanlin Zhao, et al.
Journal of Medicinal Chemistry
|
June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists
Richard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
PLOS Global Public Health
|
December 20, 2023
The effect of M. tuberculosis lineage on clinical phenotype
Duc Hong Du, Ronald B Geskus, Yanlin Zhao, et al.
Journal of Medicinal Chemistry
|
December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist
Richard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
Nature Communications
|
April 21, 2016
Corrigendum: Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis
Phelim Bradley, N Claire Gordon, Timothy M Walker, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 246) with videos related to
Sort By:
Page
of 25
Antimicrobial Agents and Chemotherapy
|
February 1, 2017
Some Synonymous and Nonsynonymous <i>gyrA</i> Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDR<i>sl</i> Assays
Adebisi Ajileye, Nataly Alvarez, Matthias Merker, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 24, 2008
P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice
Jere E Meredith, Lorin A Thompson, Jeremy H Toyn, et al.
Journal of Pharmaceutical Sciences
|
October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations
Kan He, Mingxin Qian, Harvey Wong, et al.
PLOS Global Public Health
|
August 23, 2024
Correction: The effect of M. tuberculosis lineage on clinical phenotype
Duc Hong Du, Ronald B Geskus, Yanlin Zhao, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2010
Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1
Lawrence R Marcin, Mendi A Higgins, F Christopher Zusi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 30, 2023
The effect of <i>M. tuberculosis</i> lineage on clinical phenotype
Duc Hong Du, Ronald B Geskus, Yanlin Zhao, et al.
Journal of Medicinal Chemistry
|
June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists
Richard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
PLOS Global Public Health
|
December 20, 2023
The effect of M. tuberculosis lineage on clinical phenotype
Duc Hong Du, Ronald B Geskus, Yanlin Zhao, et al.
Journal of Medicinal Chemistry
|
December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist
Richard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
Nature Communications
|
April 21, 2016
Corrigendum: Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis
Phelim Bradley, N Claire Gordon, Timothy M Walker, et al.
Page
of 25